Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.80 Insider Own0.50% Shs Outstand208.72M Perf Week-1.39%
Market Cap20.16B Forward P/E485.33 EPS next Y0.20 Insider Trans-6.67% Shs Float208.72M Perf Month-8.00%
Income-154.60M PEG- EPS next Q-0.49 Inst Own95.50% Short Float2.92% Perf Quarter-22.71%
Sales1.42B P/S14.21 EPS this Y-337.00% Inst Trans2.23% Short Ratio3.33 Perf Half Y-17.06%
Book/sh8.50 P/B11.36 EPS next Y115.60% ROA-8.50% Target Price148.63 Perf Year-6.12%
Cash/sh6.14 P/C15.73 EPS next 5Y- ROE-14.80% 52W Range92.91 - 153.15 Perf YTD-3.68%
Dividend- P/FCF- EPS past 5Y18.70% ROI13.20% 52W High-36.94% Beta0.75
Dividend %- Quick Ratio4.80 Sales past 5Y63.60% Gross Margin94.60% 52W Low3.95% ATR3.65
Employees980 Current Ratio4.80 Sales Q/Q41.60% Oper. Margin-4.90% RSI (14)39.62 Volatility3.71% 3.43%
OptionableYes Debt/Eq0.01 EPS Q/Q-10.70% Profit Margin-10.90% Rel Volume0.70 Prev Close94.83
ShortableYes LT Debt/Eq0.01 EarningsOct 31 BMO Payout- Avg Volume1.83M Price96.58
Recom2.00 SMA20-3.20% SMA50-10.21% SMA200-22.04% Volume1,277,511 Change1.85%
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-10-17Initiated Gabelli & Co Buy $185
Apr-07-17Reiterated Barclays Overweight $135 → $185
Apr-05-17Downgrade Raymond James Outperform → Mkt Perform
Apr-04-17Reiterated RBC Capital Mkts Outperform $138 → $157
Mar-09-17Initiated UBS Neutral $140
Mar-02-17Initiated Instinet Buy $148
Feb-15-17Reiterated RBC Capital Mkts Outperform $123 → $138
Jan-23-17Initiated Credit Suisse Outperform
Oct-12-16Reiterated RBC Capital Mkts Outperform $106 → $113
Sep-29-16Upgrade Raymond James Mkt Perform → Outperform
Aug-10-16Reiterated Leerink Partners Outperform $85 → $95
Aug-10-16Reiterated Barclays Overweight $85 → $100
Aug-05-16Initiated SunTrust Buy
Dec-10-17 07:31AM  Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera Business Wire
Dec-04-17 09:03AM  What Analysts Recommend for United Therapeutics in November 2017 Market Realist
08:01AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Dec-01-17 08:04AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-30-17 08:05AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-28-17 11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
Nov-21-17 11:56AM  ETFs with exposure to Incyte Corp. : November 21, 2017 Capital Cube
08:30AM  Six promising stocks to buy for the biotech rebound ahead MarketWatch
08:20AM  Todays Research Reports on Trending Tickers: Incyte Corporation and Repros Therapeutics Inc. ACCESSWIRE
Nov-20-17 06:54PM  Is Incyte Corporations (INCY) Liquidity As Good As Its Solvency? Simply Wall St. -6.18%
08:07AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-16-17 07:55AM  Incyte (INCY) Initiates Essential Thrombocythemia Trial Zacks
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
08:00AM  Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global Discovering Underlying Factors of Influence GlobeNewswire
07:30AM  Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia Business Wire
Nov-14-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-07-17 07:07PM  Cramer's lightning round: Don't give up on Incyte CNBC Videos
06:52PM  Cramer's lightning round: Don't give up on Incyte CNBC
07:30AM  Featured Company News - Alnylam Shares Positive Preliminary Results from Ongoing Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 ACCESSWIRE
Nov-06-17 11:49AM  ETFs with exposure to Incyte Corp. : November 6, 2017 Capital Cube
10:48AM  The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket Benzinga
Nov-05-17 09:00AM  ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo PR Newswire
Nov-04-17 12:02PM  November Top Growth Stocks Simply Wall St.
Nov-03-17 10:05AM  Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-01-17 03:05PM  Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal Zacks
01:56PM  Edited Transcript of INCY earnings conference call or presentation 31-Oct-17 2:00pm GMT Thomson Reuters StreetEvents
11:14AM  More Than 30 Abstracts Highlighting Data from Incytes Portfolio Accepted for Presentation at the 59th Annual ASH Meeting Business Wire
09:24AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Incyte Corporation and Array BioPharma ACCESSWIRE
Oct-31-17 04:31PM  Incyte Rises On A Beat-And-Raise, Expanding Deal With AstraZeneca Investor's Business Daily
04:00PM  Incyte, AstraZeneca expand collaboration on potential lung cancer therapy American City Business Journals
09:26AM  Geron Shares Rise on Fast Track Designation -- Biotech Movers TheStreet.com
07:55AM  Incyte Corporation to Host Earnings Call ACCESSWIRE
07:45AM  Incyte tops Street 3Q forecasts Associated Press
07:05AM  What Does Incyte Corporations (INCY) Share Price Indicate? Simply Wall St.
07:00AM  Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs Business Wire
04:43AM  AstraZeneca plans new pivotal lung cancer trial with Incyte Reuters
03:00AM  Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer Business Wire
Oct-30-17 04:30PM  Incyte Names New Member to Its Board of Directors Business Wire
10:41AM  What's in the Cards for PFE, INCY and ACOR in Q3 Earnings? Zacks
08:15AM  Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite Zacks
Oct-27-17 09:35AM  Get Rid of These 5 Toxic Stocks or Sell Short for Profit Zacks
08:48AM  Why Incyte (INCY) Might Surprise This Earnings Season Zacks
Oct-26-17 03:10PM  Why this Rockville biotech's stock made a big jump this week American City Business Journals
Oct-25-17 06:07PM  Why MacroGenics, Inc. Stock Soared Today Motley Fool
01:00PM  Incyte enters into licensing deal valued at up to $900M American City Business Journals
09:28AM  MacroGenics Soars on Collaboration with Incyte -- Biotech Movers TheStreet.com
06:45AM  Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012 Business Wire
Oct-24-17 10:57AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
10:03AM  Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco Zacks
08:02AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Oct-23-17 02:30PM  How Earnings Will Fuel Biotech's Bull Run: BMO Capital Investopedia
Oct-20-17 02:39PM  Gilead Sciences Stock: Performance in 3Q17 Market Realist
Oct-19-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Oct-16-17 03:04PM  Incyte Might Win a Cancer-Drug Battle But Lose the War Bloomberg
09:54AM  ETFs with exposure to Incyte Corp. : October 16, 2017 Capital Cube
08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
07:50AM  Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease Investor's Business Daily
Oct-12-17 04:10PM  Incyte to Report Third Quarter Financial Results Business Wire
Oct-10-17 07:30AM  One Of Biotech's Hottest Names Embraces Pharma's Bygone Era Forbes
Oct-06-17 02:58PM  Take a look: Incyte unveils new global headquarters in Wilmington American City Business Journals
09:00AM  Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware Business Wire
Oct-05-17 11:06AM  ETFs with exposure to Incyte Corp. : October 5, 2017 Capital Cube
Oct-04-17 11:40AM  Cancer-Cure Makers Make Great Takeover Stocks Forbes
Sep-28-17 07:32PM  3 Stocks That Turned $7,000 Into $130,200 Motley Fool
09:20AM  Agenus (AGEN) Remains Focused on Drug Development Programs Zacks
Sep-27-17 08:06AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Sep-26-17 08:06AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Sep-25-17 02:30PM  12 Stocks That Will Push the S&P 500 Higher Investopedia
10:40AM  ETFs with exposure to Incyte Corp. : September 25, 2017 Capital Cube
08:46AM  Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite Zacks
Sep-24-17 09:09AM  3 Monster Biotech Stocks in the Making Motley Fool
Sep-21-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-20-17 08:01AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Sep-19-17 04:05PM  Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress GlobeNewswire
Sep-18-17 10:00AM  Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Sep-15-17 09:51AM  Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study Zacks
Sep-14-17 02:49PM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
01:19PM  Have Investors Already Priced In Incyte Corporations (INCY) Growth? Simply Wall St.
11:35AM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
09:00AM  Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-13-17 06:39PM  ETFs with exposure to Incyte Corp. : September 13, 2017 Capital Cube
Sep-12-17 09:28AM  This Analyst Predicts Bullish Growth Outlook For Incyte Benzinga
Sep-11-17 02:30PM  Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
10:44AM  Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017 Capital Cube
10:21AM  [$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances Financial Times
Sep-09-17 08:49AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
08:45AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with Mercks KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
Sep-08-17 10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com
08:35AM  Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock Business Wire
Sep-07-17 05:28PM  Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock Business Wire
Sep-05-17 11:50AM  Alexion: Quite a Comeback Barrons.com
10:46AM  The Key Reason Incyte Corporation Added $850 Million in Market Cap in August Motley Fool
Sep-01-17 05:32PM  Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda Zacks
05:04PM  Top Research Reports for Bank of America, Pepsi & American Express Zacks
09:00AM  Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month Business Wire
Aug-31-17 01:39PM  Why $475,000 isn't actually that expensive for Novartis's new drug Yahoo Finance
11:10AM  Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected Zacks
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huber Reid MEVP, Chief Scientific OfficerDec 01Sale98.0169668,21538,205Dec 05 04:01 PM
FRIEDMAN PAUL ADirectorNov 16Sale105.2428,5073,000,077269,011Nov 20 04:25 PM
GRYSKA DAVID WExecutive Vice President, CFONov 02Sale105.633,915413,54113,992Nov 03 04:01 PM
Hoppenot HerveChairman / CEOSep 18Sale119.4570,5028,421,464299,004Sep 20 04:28 PM
Flannelly Barry PEVP & General Manager USSep 14Sale124.2571488,71514,782Sep 15 04:11 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy132.00100,00013,200,00029,247,347Sep 08 05:06 PM
Trower PaulPrincipal Accounting OfficerSep 05Option Exercise17.793,00053,37014,853Sep 07 04:04 PM
Trower PaulPrincipal Accounting OfficerSep 05Sale138.413,000415,23011,853Sep 07 04:04 PM
Siegel Eric H.EVP, General CounselSep 01Option Exercise64.551,820117,48123,553Sep 05 04:27 PM
Siegel Eric H.EVP, General CounselSep 01Sale137.401,820250,06821,733Sep 05 04:27 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Option Exercise17.7920,000355,80055,067Sep 05 04:22 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Sale140.0020,0002,800,00035,067Sep 05 04:22 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Option Exercise89.522,111188,97420,276Aug 31 04:13 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Sale125.002,111263,87518,165Aug 31 04:13 PM
Trower PaulPrincipal Accounting OfficerAug 04Option Exercise17.793,00053,37014,853Aug 07 04:33 PM
Trower PaulPrincipal Accounting OfficerAug 04Sale125.253,000375,75011,853Aug 07 04:33 PM
Siegel Eric H.EVP, General CounselAug 01Option Exercise64.551,820117,48123,553Aug 03 04:54 PM
Siegel Eric H.EVP, General CounselAug 01Sale132.921,820241,91421,733Aug 03 04:54 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Option Exercise85.686,485555,64124,650Jul 21 04:01 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Sale131.096,485850,11918,165Jul 21 04:01 PM
Trower PaulPrincipal Accounting OfficerJul 05Option Exercise17.793,00053,37015,148Jul 07 05:02 PM
Trower PaulPrincipal Accounting OfficerJul 05Sale126.183,000378,54012,148Jul 07 05:02 PM
Siegel Eric H.EVP, General CounselJul 03Option Exercise64.551,820117,48120,036Jul 05 06:20 PM
Siegel Eric H.EVP, General CounselJul 03Sale126.201,820229,68418,216Jul 05 06:20 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Option Exercise73.2159943,85319,614Jul 05 04:12 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Sale129.7459977,71419,015Jul 05 04:12 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Option Exercise91.459,883903,82424,531Jun 22 04:29 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Sale125.009,8831,235,37514,648Jun 22 04:29 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Option Exercise73.2116,7561,226,70735,771Jun 14 04:50 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Sale116.6016,7561,953,75019,015Jun 14 04:50 PM
Siegel Eric H.EVP, General CounselJun 06Option Exercise66.661,29286,12718,216Jun 07 04:21 PM
Trower PaulPrincipal Accounting OfficerJun 05Option Exercise17.793,00053,37013,950Jun 07 04:12 PM
Trower PaulPrincipal Accounting OfficerJun 05Sale132.503,000397,50010,950Jun 07 04:12 PM
Siegel Eric H.EVP, General CounselJun 01Option Exercise64.551,820117,48118,744Jun 02 04:22 PM
Siegel Eric H.EVP, General CounselJun 01Sale130.001,820236,60016,924Jun 02 04:22 PM
BIENAIME JEAN JACQUESDirectorMay 31Buy131.8050065,9004,677Jun 02 04:14 PM
BIENAIME JEAN JACQUESDirectorMay 15Buy115.0050057,5004,177May 17 04:18 PM
Huber Reid MEVP, Chief Scientific OfficerMay 08Sale119.218,5771,022,46436,037May 09 04:38 PM
Trower PaulPrincipal Accounting OfficerMay 05Option Exercise17.793,00053,37013,950May 09 04:17 PM
Trower PaulPrincipal Accounting OfficerMay 05Sale121.703,000365,10010,950May 09 04:17 PM
Siegel Eric H.EVP, General CounselMay 01Option Exercise64.551,820117,48118,744May 02 05:52 PM
Flannelly Barry PEVP & General Manager USMay 01Option Exercise48.442,06499,98017,949May 02 06:01 PM
Flannelly Barry PEVP & General Manager USMay 01Sale124.735,296660,56412,653May 02 06:01 PM
Siegel Eric H.EVP, General CounselMay 01Sale124.731,820227,00916,924May 02 05:52 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Option Exercise67.061,38993,14620,404May 02 05:39 PM
BIENAIME JEAN JACQUESDirectorApr 28Buy124.2650062,1303,677May 02 04:31 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Sale124.261,389172,59719,015May 02 05:39 PM
BAKER BROS. ADVISORS LPDirectorApr 27Option Exercise7.2660,000435,60029,161,795Apr 28 05:10 PM
BIENAIME JEAN JACQUESDirectorApr 13Buy139.661,000139,6603,177Apr 17 04:56 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Option Exercise67.0641,5282,784,86860,543Apr 11 04:14 PM
Siegel Eric H.EVP, General CounselApr 10Option Exercise39.134,043158,20620,828Apr 11 04:19 PM
Siegel Eric H.EVP, General CounselApr 10Sale140.184,043566,74816,785Apr 11 04:19 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Sale138.0041,5285,730,86419,015Apr 11 04:14 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Option Exercise89.7932,0002,873,16046,648Apr 11 04:24 PM
BIENAIME JEAN JACQUESDirectorApr 07Buy139.481,000139,4802,177Apr 11 04:06 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Sale137.8832,0004,412,31014,648Apr 11 04:24 PM
FRIEDMAN PAUL ADirectorMar 17Option Exercise18.3241,693763,816339,211Mar 20 04:10 PM
BROOKE PAUL ADirectorMar 17Option Exercise7.2620,000145,200216,756Mar 20 04:14 PM
BROOKE PAUL ADirectorMar 17Sale147.7520,0002,955,000196,756Mar 20 04:14 PM
FRIEDMAN PAUL ADirectorMar 17Sale148.1841,6936,178,069297,518Mar 20 04:10 PM
FRIEDMAN PAUL ADirectorMar 16Option Exercise18.328,307152,184305,825Mar 20 04:10 PM
FRIEDMAN PAUL ADirectorMar 16Sale151.458,3071,258,095297,518Mar 20 04:10 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 27Sale131.882,008264,81552,262Mar 01 04:56 PM
FRIEDMAN PAUL ADirectorFeb 23Option Exercise18.3250,000916,000347,518Feb 27 04:54 PM
FRIEDMAN PAUL ADirectorFeb 23Sale120.3250,0006,016,000297,518Feb 27 04:54 PM
Huber Reid MEVP, Chief Scientific OfficerJan 09Sale113.5511,7391,332,96352,185Jan 11 04:21 PM